Charles River Laboratories (CRL) Tops Q4 EPS by 4c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $288.50 -1.65%
EPS Growth %: +21.8%
Financial Fact:
Income from continuing operations before income taxes: 53.26M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Income from continuing operations before income taxes: 53.26M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.04 better than the analyst estimate of $2.35. Revenue for the quarter came in at $994.2 million versus the consensus estimate of $987.2 million.
GUIDANCE:
Charles River Laboratories sees FY2026 EPS of $10.70-$11.20, versus the consensus of $10.89.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
- Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
